
| Revenue | $1 - $10 million See Exact Annual Revenue |
|---|---|
| Employees | 1 - 10Exact Company Size |
| Primary Industry | 5241 Insurance Carriers |
| Additional NAICS Codes | 5417 Scientific Research & Development Services 541711 Research & Development in Biotechnology |
| Address | 1929 Zonal Ave Los Angeles, CA 90033 |
| Vasgene Therapeutics | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
|---|---|---|---|
| 2025 | $1 - $10 million Details in Premium Report | ||
| 2024 | |||
| 2023 | |||
| 2021 | |||
| 2020 | |||
| 2019 | |||
|
1-Year Growth Rate: 3-Year Growth Rate (CAGR): | ![]() |
| Vasgene Therapeutics P&L | $ Millions |
|---|---|
| Revenue (Sales) | ![]() |
| Cost of Goods Sold | |
| Gross Profit | |
Operating Expenses | |
| Advertising | |
| Salaries and wages | |
| Other Operating Expenses | |
| Total Operating Expenses | |
| Operating Income | |
| EBITDA | |
| EBIT (Earnings Before Interest and Taxes) | |
| Net Profit | |
| Trademark | Date |
|---|---|
| VASGENE DIAGNOSTIC RECOMBINANT VECTORS FOR CLONING, MANIPULATING AND EXPRESSING RECOMBINANT DNA FOR SCIENTIFIC AND MEDICAL RESEARCH USE; DIAGNOSTIC CHEMICAL, BIOCHEMICAL, BIOLOGICAL AND BIOTECHNOLOGICAL PREPARATIONS AND SUBSTANCES, NAMELY, RECOMBINANT VECTORS FOR SCIENTIFIC AND MEDICAL RESEARCH USE; CHEMICAL, BIOCHEMICAL, BIOLOGICAL AND BIOTECHNOLOGICAL PREPARATIONS AND SUBSTANCES, NAMELY, CELL GROWTH SUPPORT STRUCTURES AND SUBSTRATES FOR USE IN CELL CULTURES AND INDUSTRIAL, SCIENTIFIC AND MEDICAL RESEARCH; CHEMICAL, BIOCHEMICAL, BIOLOGICAL AND BIOTECHNOLOGICAL PREPARATIONS AND SUBSTANCES FOR USE IN THE MANUFACTURE OF MEDICINES, PHARMACEUTICALS, DIAGNOSTICS, VACCINES, ANTIBODIES AND BIOLOGICAL MOLECULES; SYNTHETIC RESINS, PREPARATIONS AND SUBSTANCES FOR USE IN THE MANUFACTURE OF MEDICINES, PHARMACEUTICALS, DIAGNOSTICS, VACCINES, ANTIBODIES AND BIOLOGICAL MOLECULES; AND AUXILIARY PREPARATIONS, CARRIERS AND SUBSTANCES FOR USE IN THE MANUFACTURE OF MEDICINES, PHARMACEUTICALS, DIAGNOSTICS, VACCINES, ANTIBODIES AND BIOLOGICAL MOLECULES | 05/20/2002 |
| VEGLIN [ PHARMACEUTICAL PREPARATIONS AND SUBSTANCES, NAMELY, THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS-RELATED DISEASES AND DISORDERS, CHRONIC INFLAMMATORY DISEASES AND DISORDERS, MULTIPLE SCLEROSIS, PSORIASIS, ARTHRITIS, SURGICAL ADHESIONS AND CARDIOVASCULAR GRAFTS; ] PHARMACEUTICAL PREPARATIONS AND SUBSTANCES, NAMELY, ANGIOGENESIS INHIBITOR PROTEIN COMPOSITIONS FOR THE TREATMENT OF DISEASES, DISORDERS AND BIOLOGICAL PROCESSES THAT ARE MEDIATED BY ANGIOGENESIS, NAMELY, CANCER, [ MACULAR DEGENERATION, DIABETIC RETINOPATHY, CROHN'S DISEASE, PSORIASIS AND ARTHRITIS; ] PHARMACEUTICAL PREPARATIONS AND SUBSTANCES, NAMELY, RECOMBINANT VECTORS FOR CLONING, MANIPULATING OR EXPRESSING RECOMBINANT DNA FOR MEDICAL USE; PHARMACEUTICAL PREPARATIONS AND SUBSTANCES, NAMELY, RECOMBINANT VECTORS FOR LABORATORIES, DIAGNOSTICS AND ANALYTICS FOR MEDICAL USE | 02/19/2002 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| CENTRUM VALLEY HOLDINGS | Clarion, IA | 100 |
| ELEVANCE HEALTH | Indianapolis, IN | 44 |
| SECURIAN LIFE INSURANCE | Saint Paul, MN | 33 |
| ATH HOLDING | Indianapolis, IN | 31 |
| HUMANA | Louisville, KY | 30 |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE | Bloomington, IL | 26 |
| AMALGAMATED LIFE INSURANCE COMPANY EMPLOYEE BENEFIT FUND | White Plains, NY | 25 |
| PRUDENTIAL INSURANCE | Newark, NJ | 24 |
| AMERICAN INTERNATIONAL GROUP | New York, NY | 13 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| MERCURY INSURANCE SERVICES | Los Angeles, CA | 100 |
| COOPERATIVE OF AMERICAN PHYSICIANS | Los Angeles, CA | 4 |
| UNISOURCE NATIONAL LENDER SERVICES | Los Angeles, CA | 2 |
| GREG FACKTOR & ACCOCIATES | Los Angeles, CA | 0 |
| 3INSYS LIMITED LIABILITY | Los Angeles, CA | 0 |
| VASGENE THERAPEUTICS | Los Angeles, CA | 0 |
| Company | Revenue ($ MM) |
|---|---|
![]() | |